According to a regulatory filing, members of Humana (HUM) Inc.’s senior management team are scheduled to meet with investors and analysts at various meetings between September 1, 2025 and September 30, 2025. During these meetings, the company intends to reaffirm its guidance of approximately $13.77 in diluted earnings per common share or approximately $17.00 in adjusted earnings per common share, in each case for the year ending December 31, 2025. This guidance is consistent with the guidance issued in the Company’s press release dated July 30, 2025. As indicated on the company’s second quarter 2025 earnings call on July 30, 2025, the company will not be commenting on 2026 Medicare Advantage Star Ratings until the Centers for Medicare and Medicaid Services releases final 2026 MA Star Ratings data in October.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana announces musculoskeletal care agreements with Vori Health, HOPCo
- Humana price target raised to $322 from $283 at RBC Capital
- Quipt Home Medical price target raised to $2.30 from $1.70 at Canaccord
- Simon Property, Humana partner on health initiative
- Judges reject 2 cases challenging Medicare negotiation, The Hill reports